Dr. Messerschmidt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
270 Curwen Rd
Bryn Mawr, PA 19010Phone+1 610-613-3882Fax+1 610-527-4857
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982
Letterman Army Medical CenterResidency, Internal Medicine, 1977 - 1979
Kaiser Permanente Northern California (San Francisco)Internship, Internal Medicine, 1976 - 1977
Oregon Health and Science University School of MedicineClass of 1976
Certifications & Licensure
CA State Medical License 2016 - 2022
PA State Medical License 2011 - 2022
TX State Medical License 1984 - 2022
IN State Medical License 2012 - 2019
FL State Medical License 1987 - 1998
MI State Medical License 1987 - 1992
MD State Medical License 1979 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy Start of enrollment: 2016 Apr 12
Publications & Presentations
PubMed
- 30 citationsExtended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D...Joseph P. Balint, Elizabeth Gabitzsch, Adrian Rice, Yvette Latchman, Younong Xu
Cancer Immunology, Immunotherapy. 2015-05-09 - 15 citationsUse of protein A immunoadsorption as a treatment for thrombocytopenia in HIV-infected homosexual men: a retrospective evaluation of 37 cases.Snyder Hw, Juergen H. Bertram, David H. Henry, Dobri D. Kiprov, Benny Wb
AIDS. 1991-10-01 - 56 citationsHow Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent AdvancesJonathan L. Messerschmidt, George C. Prendergast, Gerald L. Messerschmidt
The Oncologist. 2016-02-01
Press Mentions
Immunomic Therapeutics’ VP, Clinical Development to Participate at Precision Medicine’s Webinar on Oncolytic Therapeutic DevelopmentSeptember 23rd, 2020
ACT Oncology Appoints New Chief Medical OfficerOctober 23rd, 2015
ACT Oncology Appoints New Chief Medical OfficerOctober 22nd, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
